NetworkNewsWire Announces Publication that Highlig

NEW YORK, NY--(Marketwired - Jun 16, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring India Globalization Capital, Inc. ( NYSE MKT : IGC ), an NNW client positioned as a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions, including Alzheimer's disease.

The publication, entitled, "Pharmaceutical Leaders Pave the Way to New Alzheimer's Treatments," discusses various treatment options for Alzheimer's disease and the publicly traded companies developing them.

To view the full publication, visit: https://www.networknewswire.com/pharmaceutica...reatments/

"While industry behemoths like Pfizer (PFE) and Novartis (NVS) are obvious contenders, India Globalization Capital (IGC) is the first cannabis pharmaceutical company to focus on Alzheimer's disease. While there are more than a dozen publicly traded cannabis pharmaceutical stocks on the market, most of them with market caps much larger than IGC's $12 million, IGC is so far the only one to apply its cannabis-therapies to the treatment of Alzheimer's.

"IGC is aggressively advancing its unique position, and earlier this week announced ( http://nnw.fm/3QaWV ) that it has acquired the exclusive rights to a THC-based treatment for Alzheimer's, moving the company one step closer to clinical trials for its Alzheimer's product.

"Under a definitive license agreement with the University of South Florida, IGC is the exclusive licensee of a patent filing for the use of tetrahydrocannabinol (THC) as a potential therapeutic agent for the disease. The patent, entitled "THC as a Potential Therapeutic Agent for Alzheimer's Disease," claims discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is what occurs in Alzheimer's disease and causes cognitive decline."

About IGC

In the United States, the company develops cannabis-based therapies. IGC has assembled a portfolio of patent filings that encompasses the indications of Pain, Seizures, Epilepsy, and Cachexia using phytocannabinoids. The company is based in Bethesda, Maryland.

For more information, visit http://www.igcinc.us

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and contributing writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://nnw.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.